Ichikawa Wataru

Researcher

基本情報

Profile and Settings

• 氏名

  Ichikawa Wataru

Affiliation

• Medical Oncology, Professor

Location

• Fujigaoka Hospital

Degree

• Doctor of Medical Science, Tokyo Medical and Dental University, Nov. 1995

Achievements

Published Papers

• Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study, Hiroo Ishida; Yu Sunakawa; Yasuhiro Kodera; Kazuhiro Yoshida; Mitsugu Kochi; Yoshihiro Kakeji; Takeshi Sano; Masahiro Takeuchi; Wataru Ichikawa; Masashi Fujii, European Journal of Cancer, 219, Mar. 2025, Peer-reviewed, DOI:10.1016/j.ejca.2025.115322
• Tumor response predicts survival time of monotherapy for advanced gastric cancer: A sub-group analysis of the DELIVER trial (JACCRO GC-08), Y. Sunakawa, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, M. Takahashi, J. Matsuyama, H. Yabusaki, A. Makiyama, T. Suzuki, M. Tsuda, H. Yasui, J. Hihara, A. Takeno, E. Inoue, W. Ichikawa, M. Fujii, The Oncologist, oyae056, Apr. 2024, Peer-reviewed, DOI:10.1093/oncolo/oyae056
• Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese phase III trials., H. Arai, M. Takeuchi, W. Ichikawa, K. Shitara, Y. Sunakawa, K. Oba, W. Koizumi, Y. Sakata, H. Furukawa, Y. Yamada, M. Takeuchi, M. Fujii, Cancer Medicine, 13(1):6818 - 6818, Dec. 2023, Peer-reviewed, DOI:10.1002/cam4.6818
• Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study, Y. Kodera, K. Yoshida, M. Kochi, T. Sano, W. Ichikawa, Y. Kakeji, Y. Sunakawa, M. Takeuchi, M. Fujii, Gastric Cancer, 26(6):1063 - 1068, Nov. 2023, Peer-reviewed, DOI:10.1007/s10120-023-01419-9
• Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16, H. Yasui, Y. Okita, M. Nakamura, T. Sagawa, T. Watanabe, K. Kataoka, D. Manaka, K. Shiraishi, N. Akazawa, T. Okuno, T. Shimura, M. Shiozawa, Y. Sunakawa, H. Ota, M. Kotaka, H. Okuyama, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji, ESMO Open, 8(5):101636 - 101636, Oct. 2023, Peer-reviewed, DOI:10.1016/j.esmoop.2023.101636
• BEETS (JACCRO CC-18) trial: an observational and translational study for BRAF mutated metastatic colorectal cancer (Clinical Trial Protocol), C. Inagaki, R. Matoba, S. Yuki, M. Shiozawa, A. Tsuji, E. Inoue, K. Muro, W. Ichikawa, M. Fujii, Y. Sunakawa, Future Oncology, 19(17):1165 - 1174, Jun. 2023, Peer-reviewed, DOI:0.2217/fon-2023-0209
• A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09), R. Kawabata, N. Izawa, T. Suzuki, Y. Nagahisa, K. Nishikawa, M. Takahashi, M. Nakamura, A. Ishiguro, H. Katsuya, J. Hihara, D. Manaka, Y. Negoro, A. Tsuji, T. Takahashi, M. Kochi, M. Azuma, S. Kadowaki, H. Michimae, Y. Sunakawa, W. Ichikawa, M. Fujii, Targeted Oncology, 18(3):359 - 368, May 2023, Peer-reviewed, DOI:10.1007/s11523-023-00961-x
• Soluble PD-L1 predicts prognosis for gastric cancer patients treated with nivolumab: blood-based biomarker analysis for the DELIVER trial., H. Kawakami, Y. Sunakawa, E. Inoue, R. Matoba, K. Noda, T. Sato, C. Suminaka, M. Yamaki, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, H. Yabusaki, J. Matsuyama, M. Takahashi, A. Makiyama, H. Hayashi, K. Chamoto, T. Honjo, K. Nakagawa, W. Ichikawa, M. Fujii, European Journal of Cancer, Feb. 2023, Peer-reviewed, DOI:10.1016/j.ejca.2023.02.003
• Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis, Azami T, Takano Y, Noda J, Yamawaki M, Yoshida E, Niiya F, Maruoka N, Ogawa T, Ichikawa W, Nagahama, Clinical Journal of Gastroenterology, Aug. 2022, Peer-reviewed, DOI:10.1007/s12328-022-01651-3
• Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of 1st-line FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer (JACCRO CC-11), Y. Sunakawa, H. Satake, J. Usher, Y. James, Y. Miyamoto, M. Nakamura, M. Kataoka, M. Shiozawa, A. Takagane, T. Terazawa, T. Watanabe, K. Ishiguro, C. Tanaka, M. Takeuchi, M. Fujii, K. Danenberg, P.V. Danenberg, H-J. Lenz, T. Sekikawa, W. Ichikawa, ESMO Open, 7(3), Jun. 2022, Peer-reviewed, DOI:https://doi.org/10.1016/j.esmoop.2022.100512
• Phase II study of S-1 and Irinotecan plus Bevacizumab as second-line treatment for patients with metastatic colorectal cancer resistant to the Fluoropyrimidine-oxaliplatin-cetuximab regimen., Hiroaki Tanioka, Ken Shimada, Akihito Tsuji, Mitsugu Kochi, Ho Min Kim, Takao Takahashi, Tadamichi Denda, Akinori Takagane, Takanori Watanabe, Masahito Kotaka, Masato Nakamura, Yu Sunakawa, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Anticancer Research, 42(5):2675 - 2681, May 2022, Peer-reviewed, DOI:10.21873/anticanres.15745
• Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial, Chin K, Takahari D, Kawabata R, Hosaka H, Saitou SO, Shiraishi T, Yabusaki H, Goto M, Nakamura M, Imamura H, Shindo Y, Nagashima F, Ichikawa W, Saotome T, Yamamoto W, Ishizuka N, Yamaguchi K., Anticancer Research, 42(5):2683 - 2687, May 2022, Peer-reviewed, DOI:10.21873/anticanres.15746
• Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients, KUBOTA Yutaro;FUJITA Ken-ichi;TAKAHASHI Takehiro;SUNAKAWA Yu;ISHIDA Hiroo;HAMADA Kazuyuki;ICHIKAWA Wataru;TSUNODA Takuya;SHIMADA Kazuhiro;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, Clin Pharmacol Ther, 108(3):586 - 595, Sep. 2020, Peer-reviewed
• Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients, KUBOTA Yutaro;FUJITA Ken-ichi;TAKAHASHI Takehiro;SUNAKAWA Yu;ISHIDA Hiroo;HAMADA Kazuyuki;ICHIKAWA Wataru;TSUNODA Takuya;SHIMADA Kazuhiro;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, Clin Pharmacol Ther, 108(3):586 - 595, Sep. 2020, Peer-reviewed
• Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer., SUNAKAWA Yu;MOGUSHI Kaoru;LENZ Heinz-Josef;ZHANG Wu;TSUJI Akihito;TAKAHASHI Takehiro;DENDA Tadamichi;SHIMADA Ken;KOCHI Mitsugu;NAKAMURA Masato;KOTAKA Masahiro;SEGAWA Yoshihiko;TANIOKA Hiroaki;NEGORO Yuji;MORAN Miriana;ASTROW Stephanie H;HSIANG Jack;STEPHENS Craig;FUJII Masashi;ICHIKAWA Wataru, Mol Cancer Ther, 17(12):2788 - 2795, Dec. 2018, Peer-reviewed
• Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer., SUNAKAWA Yu;YANG Dongyun;CAO Shu;ZHANG Wu;MORAN Miriana;ASTROW Stephanie H;HSIANG Jack;STEPHENS Craig;TSUJI Akihito;TAKAHASHI Takehiro;TANIOKA Hiroaki;NEGORO Yuji;TAKAGANE Akinori;TANI Satoshi;YAMAGUCHI Tatsuro;ETO Tetsuya;FUJII Masashi;ICHIKAWA Wataru;LENZ Heinz-Josef, Clin Colorectal Cancer, 17(4):e741 - e749, Dec. 2018, Peer-reviewed
• Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors., SUNAKAWA Yu;SATAKE Hironaga;ICHIKAWA Wataru, World J Gastrointest Oncol, 10(12):528 - 531, Dec. 2018, Peer-reviewed
• A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11., SATAKE H;SUNAKAWA Y;MIYAMOTO Y;NAKAMURA M;NAKAYAMA H;SHIOZAWA M;MAKIYAMA A;KOBAYASHI K;KUBOTA Yutaro;MORI M;KOTAKA M;TAKAGANE A;GOTOH M;TAKEUCHI M;FUJII M;ICHIKAWA Wataru;SEKIKAWA Takashi, Oncotarget, 9(27):18811 - 18820, Apr. 2018, Peer-reviewed
• CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer., SUNAKAWA Yu;TSUJI Akihito;DENDA Tadamichi;SEGAWA Yoshihiko;NEGORO Yuji;SHIMADA Ken;KOCHI Mitsugu;NAKAMURA Masato;KOTAKA Masahito;TANIOKA Hiroaki;TAKAGANE Akinori;TANI Satoshi;YAMAGUCHI Tatsuro;WATANABE Takanori;TAKEUCHI Masahiro;FUJII Masashi;ICHIKAWA Wataru, Target Oncol, 12(6):787 - 794, Dec. 2017, Peer-reviewed
• Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials., SUNAKAWA Yu;ICHIKAWA Wataru;TSUJI Akihito;DENDA Tadamichi;SEGAWA Yoshihiko;NEGORO Yuji;SHIMADA Ken;KOCHI Mitsugu;NAKAMURA Masato;KOTAKA Masahito;TANIOKA Hiroaki;TAKAGANE Akinori;TANI Satoshi;YAMAGUCHI Tatsuro ;WATANABE Takanori;TAKEUCHI Masahiro;FUJII Masashi;NAKAJIMA Toshifusa, Clin Colorectal Cancer, 16(3):e171 - e180, Sep. 2017, Peer-reviewed
• No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?, SUNAKAWA Yu;TSUJI Atsuhito;FUJII Masakuni;ICHIKAWA Wataru, Ann Oncol, 28(8):2030 - 2031, Aug. 2017, Peer-reviewed
• リスク予測研究　CPT-11の有害事象のリスク, 今高　博美;関川　高志;市川　度, 日本臨牀, 74(11):1847 - 1851, Nov. 2016
• Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan., TAKATA Kosuke;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru;SHIMADA Ken;SEKIKAWA Takashi;TAKI-TAKEMOTO Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, J Pharm Health Care Sci, 2(30):1 - 9, Nov. 2016, Peer-reviewed
• Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX, KAGA Yasuhiro;SUNAKAWA Yu;KUBOTA Yutaro;TAGAWA Teppei;YAMAMOTO Taikan;IKUSUE Toshikazu;UTO Yu;MIYASHITA Kouichirou;TOSHIMA Hirokazu;KOBAYASHI Kouji;HISAMATSU Atsushi;ICHIKAWA Wataru;SEKIKAWA Takashi;SHIMADA Ken;SASAKI Yasutsuna, Oncotarget, 7(41):67314 - 67320, Oct. 2016
• Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer., SUNAKAWA Yu;YANG Dongyun;MORAN Miriana;ASTROW Stephanie H;TSUJI Akihito;STEPHENS Craig;ZHANG Wu;CAO Shu;TAKAHASHI Takehiro;DENDA Tadamichi;SHIMADA Ken;KOCHI Mitsugu;NAKAMURA Masato;KOTAKA Masahito;SEGAWA Yoshihiko;MASUISHI Toshiki;TAKEUCHI Masahiro;FUJII Masashi;NAKAJIMA Toshifusa;ICHIKAWA Wataru;LENZ Heinz-Josef, Cancer Biol Ther, 17(7):751 - 759, Jul. 2016, Peer-reviewed
• A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients, MATSUNAGA Mototsugu;KANETA Toshikado;MIWA Keisuke;ICHIKAWA Wataru;FUJITA Ken-ichi;NAGASHIMA Fumio;FURUSE Junji;KAGE Masayoshi;AKAGI Yoshito;SASAKI Yasutsuna, Oncol Lett, 12(1):150 - 156, Jul. 2016, Peer-reviewed
• Crizotinib-induced pancreatic pseudocyst: a novel adverse event., ISHIDA Hiroo;ICHIKAWA Wataru;SASAKI Yasutsuna, BMJ Case Rep, :1 - 3, Sep. 2015, Peer-reviewed, DOI:10.1136/bcr-2015-211556
• Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?, SASAKI Yasutsuna;HAMADA Kazuyuki;KANETA Toshikado;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru, Cancer Sci, 106(8):1100, Aug. 2015, Peer-reviewed
• An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients., ICHIKAWA Wataru;UEHARA Keisuke;MINAMIMURA Keisuke;TANAKA Chihiro;TAKII Yasumasa;MIYAUCHI Hideaki;SADAHIRO Sotaro;FUJITA Ken-ichi;MORIWAKI Toshikazu;NAKAMURA Masato;TAKAHASHI Takehiro;TSUJI Akihito;SHINOZAKI Katsunori;MORITA Satoshi;ANDO Yuichi;OKUTANI Yukihiro;SUGIHARA Masahiro;SUGIYAMA Toru;OHASHI Yasuo;SAKATA Yuh, Br J Cancer, 112(10):1709 - 1716, May 2015, Peer-reviewed
• Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer, MATSUYAMA Masato;ISHII Hiroshi;FURUSE Junji;OHKAWA Shinichi;MAGUCHI Hiroyuki;MIZUNO Nobumasa;YAMAGUCHI Taketo;IOKA Tatsuya;AJIKI Tetsuo;IKEDA Masafumi;HAKAMADA Kenichi;YAMAMOTO Masakazu;YAMAUE Hiroki;EGUCHI Kenji;ICHIKAWA Wataru;MIYAZAKI Masaru;OHASHI Yasuo;SASAKI Yasutsuna, Invest New Drugs, 33(2):490 - 495, Apr. 2015, Peer-reviewed
• Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases, SUNAKAWA Yu;TAKAHASHI Takehiro;ICHIKAWA Wataru;SHIMADA Ken;SASAKI Yasutsuna, J Clin Oncol, 31(35):4473, Oct. 2013, Peer-reviewed, DOI:10.1200/JCO.2013.50.8713

Presentations

• Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13)., S. Natsume, T. Sekikawa, A. Takagane, K. Sawada, H. Bando, T. Yamada, H. Nakayama, Y. Uchima, T. Shiraishi, J. Kizaki, T. Furuya, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa, A. Tsuji, 第21回日本臨床腫瘍学会学術集会, 22 Feb. 2024, 名古屋
• Anti-EGFR therapy for RAS mutant mCRC without RAS mutations in ctDNA after 1st or 2nd -line chemotherapy: JACCRO CC-17., Y. Ono, N. Izawa, Y. Matsubara, S. Nishina, T. Denda, H. Ota, T. Tokunaga, L.F. Chan, Y. Shindo, H. Shimokawa, H. Fujita, K. Okamoto, T. Ishiguro, Y. Sakamoto, Y. Kagawa, H. Satake, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa, 第21回日本臨床腫瘍学会学術集会, 22 Feb. 2024, 名古屋
• Genome-wide DNA methylation status predicts the efficacy of modified (m)-FOLFOXORI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: a biomarker study of the DEEPER trial (JACCRO CC-13AR)., K. Ouchi, A. Tsuji, M. Shiozawa, T. Kawai, H. Yasui, H. Ota, M. Kochi, D. Manaka, H. Ohori, T. Miyake, T. Yamaguchi, M. Matsuura, T. Sagawa, A. Makiyama, K. Wakamura, M. Takeuchi, W. Ichikawa, M. Fujii, C. Ishioka, Y. Sunakawa, ASCO GI, 18 Jan. 2024, Sanfrancisco, USA
• A phase II trial of CapeOX plus nivolumab for early relapsed HER-2 negative gastric cancer (JACCRO GC-11: FirSTAR trial), H. Arai, E. Inoue, M. Terashima, E. Baba, N. Matsuhashi, K. Muro, T. Yamaguchi, S. Yuki, Y. Sunakawa, W. Ichikawa, M. Fujii, ASCO GI, 18 Jan. 2024, SanFrancisco, USA
• SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarker for nivolumab in gastric cancer., C. Inagaki, R. Matoba, H, Iijima, J. Hihara, H. Yasui, M. Tsuda, T. Suzuki, A. Makiyama, H. Yabusaki, J. Matsuyama, M. Takahashi, Y. Kito, Y. Akamaru, A. Ishiguro, R. Kawabata, Y. Sakamoto, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa, ESMO, 20 Oct. 2023, Madrid, Spain
• Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): the DEEPER trial (JACCRO CC-13)., Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, M. Matsuura, Y. Shinohara, T. Miyake, T. Sagawa, C. Tanaka, S. Okamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji, ESMO, 20 Oct. 2023, Madrid, Spain
• The efficacy of anti-EGFR for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy., N. Izawa, T. Kudo, S. Yuki, M. Nakamura, D. Manaka, Y. Kumekawa, T. Mine, T. Okuno, H. Oda, T. Sagawa, T. Kawai, T. Shingai, M. Kotaka, K. Kobayashi, Y. Kagawa, H. Satake, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa, ESMO, 20 Oct. 2023, Madrid, Spain
• High DpR of m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided metastatic colorectal cance -Update analysis of BRAF Status in the DEEPER trial (JACCRO CC-13), D. Manaka, M. Shiozawa, T. Kawai, H. Ota, H. Yasui, T. Yabuno, M. Tei, N. Matsuhashi, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa, A. Tsuji, 第61回日本癌治療学会学術集会, 19 Oct. 2023, 横浜
• RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17)., S. Nishina, N. Izawa, M. Watanabe, T. Matsumoto, M. Kataoka, A. Sugaya, T. Kashiwada, E. Oki, A. Makiyama, Y. Yaguchi, T. Ohta, T. Toyokawa, Y. Miura, K. Kobayashi, Y. Kito, O. Muto, Y. Kagawa, S. Satake, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa, ESMO, 28 Jun. 2023, Barcelona, Spain
• Modified (m)-FOLFOXORI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO., Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, T. Kyogoku, T. Sagawa, Y. Kubota, T. Masuishi, M. Kotaka, T. Sekikawa, K. Shimada, W. Nakamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji, ESMO, 28 Jun. 2023, Barcelona, Spain
• Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08)., Y. Sunakawa, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, M. Takahashi, J. Matsuyama, H. Yabusaki, A. Makiyama, T. Suzuki, M, Tsuda, H. Yasui, J. Hihara, A. Takeno, E. Inoue, W. Ichikawa, M.Fujii, ASCO, 02 Jun. 2023
• Improved 5-years overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in the JACCRO GC-07, W. Ichikawa, K. Yoshida, Y. Kodera. M. Kitazawa, M. Horao, Y. Seto, K. Hibi, S. Kinami, M. Watanabe, S. Makino, M. Kochi, T. Sano, Y. Kakeji, M. Takeuchi, M. Fujii, ASCO, 02 Jun. 2023, Chicago, USA
• RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16AR., Y. Sunakawa, H. Yasui, M. Matsuura, T. Mine, Y. Yuasa, T. Watanabe, T. Kinjo, Y. Okita, H. Okuyama, S. Yuki, K. Miyakawa, A. Kobara, W. Ichikawa, M. Fujii, A. Tsuji, 第20回日本臨床腫瘍学会, Mar. 2023
• RAS変異型切除不能進行・再発大腸癌患者における化学療法後のctDNA中RAS遺伝子変異ステータス：RASMEX study (JACCRO CC-17), 伊澤直樹, 松原裕樹, 仁科慎一, 塩澤 学, 傳田忠道, 太田博文, 根来裕二, 田中千弘, 川上尚人, 松岡 宏, 田邊裕貴, 池永雅一, 奥田博介, 石黒 敦, 賀川義規, 佐竹悠良, 砂川 優, 竹内正弘, 市川 度, 藤井雅志, 第20回日本臨床腫瘍学会, Mar. 2023
• 抗EGFR抗体薬併用化学療法進行再発大腸癌患者に対する2次治療FOLFIRI/ラムシルマブ併用療法の第II相試験：JACCRO CC-16 Update解析, 間中 大, 辻 晃仁, 澁谷雅常, 石橋敬一郎, 薮野太一, 岡村 修, 古谷卓三, 田中千弘, 中村将人, 佐川 保, 渡邉貴紀, 塩澤　学, 砂川 優, 太田博文, 小髙雅人, 奥山浩之, 大北仁裕, 竹内正弘, 市川 度, 藤井雅志, 第20回日本臨床腫瘍学会, Mar. 2023
• RAS野生型切除不能進行再発大腸癌に対するm-FOLFOXIRI+cetuximab vs. bevacizumabの生存解析: DEEPER試験(JACCRO CC-13), 辻 晃仁, 遠藤 出, 小林建司, 宮 裕士, 楠本哲也, 湯浅康弘, 三輪啓介, 東風 貢, 佐川 保, 小髙 雅人, 久保田祐太郎, 砂川 優, 関川高志, 中村将人, 竹内正弘, 市川 度, 藤井雅志, 第20回日本臨床腫瘍学会, Mar. 2023
• Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as 2nd-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR., Y. Sunakawa, H. Yasui, M. Shiozawa, H. Takeda, N. Akazawa, T. Sagawa, K. Shiraishi, Y. Okita, H. Okuyama, S. Yuki, S. Yanaka, K. Matsushima, K. Miyakawa, A. Kobara, W. Ichikawa, M. Fujii, A. Tsuji, ASCO Gastrointestinal Cancer Symposium, Jan. 2023
• Post-recurrence survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: a post-hoc analysis of the START-2 (JACCRO GC-07)., H. Ishida, Y. Sunakawa, Y. Kodera, K. Yoshida, M. Kochi, Y. Kakeji, T. Sano, M. Takeuchi, W. Ichikawa, M. Fujii, ASCO Gastrointestinal Cancer Symposium, Jan. 2023
• Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO., Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, T. Yabuno, M. Tei, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, T. Sagawa, M. Kotaka, Y. Kubota, T. Sekikawa, M. Nakamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji, ASCO Gastrointestinal Cancer Symposium, Jan. 2023
• The subgroup analysis of tumor response by BRAF status in modified (m)-FOLFOXIRI plus cetuximab vs. bevacizumab for RAS wild-type metastatic colorectal cancer (mCRC): the DEEPER trial (JACCRO CC-13), M. Tei, A. Tsuji, N. Suzuki, M. Nakamura, Y. Fujie, M. Kochi, T. Sagawa, M. Kotaka, Y. Kubota, Y. Sunakawa, T. Sekikawa, M. Nakamura, M. Takeuchi, W. Ichikawa, M. Fujii, 第60回日本癌治療学会総会, Oct. 2022, 神戸
• Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16, K. Kataoka, A. Tsuji, K. Hiroo, S. Fujita, K. Yuge, Y. Kito, M. Fukunaga, M. Nakamura, T. Sagawa, T. Watanabe, M. Shiozawa, Y. Sunakawa, M. Takeuchi, W. Ichikawa, M. Fujii, 第60回日本癌治療学会総会, Oct. 2022, 神戸
• Angiogenesis-factors and efficacy of FOLFIRI plus ramucirumab (RAM) in 2nd-line treatment for RAS wild-type metastatic colorectal cancer (mCRC): JACCRO CC-16AR study, Y. Sunakawa, H. Yasui, M. Shiozawa, H. Takeda, N. Akazawa, T. Sagawa, K. Shiraishi, Y. Okita, H. Okuyama, S. Yuki, W. Ichikawa, M. Fujii, 第60回日本癌治療学会総会, Oct. 2022, 神戸
• Host-related biomarkers to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (進行胃がんにおけるニボルマブの毒性を予測する宿主関連バイオマーカー)(JACCRO GC-08), Y. Sunakawa, Y. Sato, T. Takayama, T. Imai, N. Sugimoto, K. Miura, S. Yuki, Y. Shindo, H. Kawakami, K. Muro, T. E. Nakajima, W. Ichikawa, M. Fujii, 日本癌学会, Sep. 2022, 横浜
• Final analysis of clinical outcomes in the DELIVER trial: An observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08), Y. Sunakawa, E. Inoue, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, M. Takahashi, J. Matsuyama, H. Yabusaki, A. Makiyama, T. Suzuki, M. Tsuda, H. Yasui, H. Kawakami, T. E. Nakajima, K. Muro, R. Matoba, W. Ichikawa, M. Fujii, ESMO 2022, Sep. 2022, Paris, France
• Efficacy by prior regimen of ramucirumab (RAM) plus FOLFIRI as 2nd-line for RAS wild-type metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibody combination therapy: Subgroup analysis of the JACCRO CC-16, Y. Okita, A. Tsuji, T. Watanabe, H. Satake, M. Goto, H. Yasui, M. Nakamura, T. Sagawa, K. Kataoka, M. Shiozawa, Y. Sunakawa, H. Ota, M. Kotaka, K. Miwa, Y. Kobayashi, H. Okuyama, M. Kochi, M. Takeuchi, W. Ichikawa, M. Fujii, ESMO 24thWorld Congress on Gastrointestinal Cancer, Jun. 2022, Barcelona, Spain
• Soluble Programmed cell Death Ligand 1 Associated with Clinical Outcome in Gastric Cancer Patients Treated with Nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR), H. Kawakami, Y. Sunakawa, E. Inoue, R. Matoba, K. Noda, T. Sato, C. Suminaka, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, H. Yabusaki, J. Matsuyama, M. Takahashi, A. Makiyama, H. Hayashi, K. Chamoto, T. Honjo, K. Nakagawa, W. Ichikawa, M. Fujii, ESMO 24thWorld Congress on Gastrointestinal Cancer, Jun. 2022, Barcelona, Spain
• Two-year update data of the DELIVER trial: Observational study of nivolumab treatment for previously treated advanced gastric cancer (JACCRO GC-08), Y. Sunakawa, E. Inoue, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, M. Takahashi, J. Matsuyama, H. Yabusaki, A. Makiyama, T. Suzuki, M. Tsuda, H. Yasui, H. Kawakami, T. E. Nakajima, K. Muro, R. Matoba, W. Ichikawa, M. Fujii, ASCO 2022, Jun. 2022, Chicago
• Molecular characteristics of gut microbiota in patients with gastric cancer: The DELIVER trial (JACCRO GC-08), 85. R. Matoba, H. Iijima, Y. Sakamoto, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, H. Yabusaki, J. Matsuyama, M. Takahashi, A. Makiyama, T. Suzuki, M. Tsuda, H. Yasui, J. Hihara, A. Takeno, H. Okuda, J. Kawawda, T. Yoshioka, H. Kawakami, T. E. Nakajima, K. Muro, W. Ichikawa, M. Fujii, Y. Sunakawa, AACR 2022, Apr. 2022, New Orleans USA
• A phase II trial of bi-weekly nab-PTX plus RAM therapy in advanced gastric cancer (GC): JACCRO GC09, 84. 長久吉雄, 伊澤直樹, 峯　孝志, 後藤昌弘, 藤井　仁, 木藤陽介, 川端良平, 中村将人, 東　瑞智, 辻　晃仁, 東風　貢, 高橋孝夫, 門脇重憲, 道前洋史, 砂川　優, 市川　度, 藤井雅志, 第94回日本胃癌学会, Mar. 2022, 横浜
• FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13), 薮野太一, 辻　晃仁, 徳永卓哉, 結城敏志, 工藤敏啓, 間下直樹, 安藤幸滋, 竹内信道, 柏田知美, 片岡政人, 東風　貢, 佐川　保, 小髙雅人, 久保田祐太郎, 砂川　優. 関川高志, 中村将人, 竹内正弘, 市川　度, 藤井雅志, 第19回日本臨床腫瘍学会, Feb. 2022, 京都
• Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody, 佐川　保, 辻　晃仁, 佐竹悠良, 中村将人, 砂川　優, 是久翔太朗, 松浦正徒, 湯浅康弘, 峯　孝志, 永野浩昭, 重安邦俊, 金城達也, 小髙雅人, 奥山浩之, 久保田祐太郎, 東風　貢, 舛石俊樹, 竹内正弘, 市川　度,藤井雅志, 第19回日本臨床腫瘍学会, Feb. 2022, 京都
• Observational study to evaluate RAS status in ctDNA for mCRC patients with RAS mutant tumor: RASMEX study (JACCRO CC-17), N. Izawa, Y. Kagawa, H. Satake, Y. Sunakawa, M. Takeuchi, W. Ichikawa, M. Fujii, 第19回日本臨床腫瘍学会, Feb. 2022, 京都
• A multicenter phase 2 trial of ramucirumab plus FOLFIRI as 2nd-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16, M. Nakamura, A. Tsuji, Y. Okita, T. Matsumoto, T. Sagawa, T. Watanabe, K. Kataoka, D. Manaka, K. Shiraishi, N. Akazawa, T. Okuno, T. Shimura, M. Shiozawa, S. Noura, Y. Sunakawa, Y. Akiyama, H. Ota, M. Takeuchi, W. Ichikawa, M. Fujii, ASCO Gastrointestinal Cancer Symposium, Jan. 2022, San Francisco
• Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: the subgroup-analysis of DEEPER trial (JACCRO CC-13), H. Satake, A. Tsuji, C. Tanaka, T. Takahashi, K. Wakamura, T. Yoshida, K. Murata, Y.Shindo, Y. Ishikawa, K. Konishi, M. Kochi, T. Sagawa, M. Kotaka, Y. Kubota, Y. Sunakawa, T. Sekikawa, M. Nakamura, M. Takeuchi, W. Ichikawa, M. Fujii, ASCO Gastrointestinal Cancer Symposium 2022, Jan. 2022, San Francisco
• M. Fujii: A Phase 2, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09), T. Suzuki, N. Izawa, R. Kawabata, K. Nishikawa, M. Takahashi, M. Nakamura, A. Ishiguro, H. Katsuya, J. Hihara, D. Manaka, Y. Negoro, M. Azuma, A. Tsuji, M. Kochi, T. Takahashi, S. Kadowaki, H. Michimae, Y. Sunakawa, W. Ichikawa, M. Fujii, ASCO Gastrointestinal Cancer Symposium 2022, Jan. 2022, San Francisco
• An observational study to evaluate RAS mutations in circulating-tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17), N. Izawa, Y. Kagawa, H. Satake, Y. Sunakawa, M. Takeuchi, W. Ichikawa, ASCO GI 2022, Jan. 2022, San Francisco
• がん患者におけるトラマドール鎮痛効果不十分に対する要因解析, 島本　一志;戸村　和希;藤宮　龍祥;松井　美月;渡邊　徹;中山　博文;市川　度;佐々木　忠徳, 第30回日本医療薬学会年会, 24 Oct. 2020, Web開催
• がん患者の皮膚角層水分量がフェンタニル貼付剤のフェンタニル残存率に及ぼす影響, 島本　一志;田島　正教;杉山　恵理花;渡邊　徹;市川　度;佐藤　均;佐々木　忠徳, 日本臨床腫瘍薬学会学術大会2019, 23 Mar. 2019, 札幌
• EGFR relative to biomarkers to predict outcome of cetuzimab-containing chemotherapy as 1st-line treatment in colorectal cancer, 砂川　優;辻　晃仁;MORAN Miriana;ASTROW Stephanie H;ZHANG Wu;高橋　威洋;傳田　忠道;嶋田　顕;東風　貢;中村　将人;竹内　正弘;藤井　雅志;中島　聰總;LENZ Heinz-Josef;市川　度, 第53回日本癌治療学会学術集会, 29 Oct. 2015, 京都
• An internally and externally validated nomogram to predict severe neutropenia in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens., ICHIKAWA Wataru;UEHARA Keisuke;MINAMIMURA Keisuke;TANAKA Chihiro;TAKII Yasumasa;MIYAUCHI Hideaki;SADAHIRO Sotaro;FUJITA Ken-ichi;MORIWAKI Toshikazu;NAKAMURA Masato;TAKAHASHI Takehiro;TSUJI Akihito;SHINOZAKI Katsunori;MORITA Satoshi;ANDO Yuichi;OKUTANI Yukihiro;SUGIHARA Masahiro;SUGIYAMA Toru;OHASHI Yasuo;SAKATA Yuh, 50th American Society of Clinical Oncology annual meeting, 31 May 2014, Chicago